Rulo A H

Rulo A H, Greve E L, Hoyng P F

This study found adding latanoprost to acetazolamide significantly further lowered IOP in glaucoma patients. This combination offers a useful strategy for managing elevated eye pressure.

Hoyng P F, Rulo A H, Greve E L, Astin M, Gjötterberg M

Latanoprost's effect on blood-retinal barrier integrity was studied in monkeys and pseudophakic humans. It didn't cause detectable leakage, suggesting safety for the barrier, but caution is advised for high-risk CME patients.

Greve E L, Rulo A H, Drance S M, Crichton A C, Mills R P, Hoyng P F

Latanoprost was studied in normal tension glaucoma. Once-daily 0.005% latanoprost significantly reduced IOP and improved ocular perfusion pressure, suggesting it's a promising, convenient treatment for NTG.

Rulo A H, Greve E L, Geijssen H C, Hoyng P F

Latanoprost significantly lowered intraocular pressure in normal-pressure glaucoma patients, with once-daily 50mcg/ml being most effective, offering a crucial treatment option for this challenging condition.

Rulo A H, Greve E L, Hoyng P F

This study found latanoprost and timolol have an additive effect in lowering elevated intraocular pressure, allowing successful combination therapy for improved glaucoma management.